



## Leveraging AI for Clinical Case Consulting & Advanced Formulation Innovation

**Jim Hrncir RPh, FAPC**

Pharmacist, Founder, Co-Owner  
*Las Colinas Pharmacy Compounding & Wellness*

1





**Our New  
Location**

**4 consult  
rooms**



2

# Consult Rooms



3

## Investigating a Rare, Medical Case: AI Learning Enabled Evidence-Based Integrative Medicine Treatment Plan



4

## Case study presented to ChatGPT- *Jim asked:*

- 68 yo female with well controlled Type-2 diabetes, using micro-dosing semaglutide from Internist MD
- Her Cardiologist MD added Jardiance 5mg to adjunctively lower glucose levels.
- Result- Continuous glucose monitoring (Libre-3), hovering around 100mg/dL.
- A few days later, patient is on vacation and becomes dissociative, nausea, headache. Rushed to local hospital ER.
- Almost immediately falls into coma lasting 3 days. DX- Ketoacidosis.
- Coincidentally- a day after she awoke from coma, her Internist called. Two weeks prior, on a lark, he had tested for Latent Onset, Auto-immune, Type 1 diabetes. The surprising results were positive.
- ChatGPT- please discuss



5

## ChatGPT Response:

This case highlights a rare but critical scenario where a patient with presumed Type 2 diabetes is later diagnosed with latent autoimmune diabetes in adults (LADA) after experiencing diabetic ketoacidosis (DKA). Let's break this down step by step.

### 1. Misdiagnosis of LADA as Type 2 Diabetes

- LADA, often referred to as Type 1.5 diabetes, is an autoimmune condition where beta-cell destruction occurs more gradually than in classic Type 1 diabetes. It is often misdiagnosed as Type 2 diabetes, especially in older adults with features of insulin resistance. Initially, patients may respond to lifestyle changes, oral medications, or even GLP-1 receptor agonists like semaglutide. However, as the autoimmune process progresses, insulin production declines, leading to hyperglycemia and, in some cases, DKA.



6



## 2. The Role of Jardiance in Precipitating Ketoacidosis

- Jardiance (empagliflozin) is an SGLT2 inhibitor that lowers blood glucose by promoting glucose excretion through urine. However, it also increases the risk of **euglycemic diabetic ketoacidosis (euDKA)**—a condition where blood glucose levels are not significantly elevated (often <250 mg/dL), but ketone production increases, leading to metabolic acidosis.
- In LADA, where endogenous insulin production is declining, the additional insulin suppression from an SGLT2 inhibitor can tip the patient into ketoacidosis.
- **Continuous Glucose Monitoring showing glucose around 100 mg/dL could have masked impending ketoacidosis**, as patients and **providers often focus on glucose levels rather than ketones**.
- This mechanism likely contributed to the coma and hospitalization.



7

## 4. Why the Autoimmune Diagnosis Was Delayed

- LADA progresses more slowly than classic Type 1 diabetes, leading to an initial false impression of Type 2 diabetes.
- It is **often diagnosed only after failure of oral agents and the onset of insulin dependence**.
- Common diagnostic markers include:
  - **GAD-65 antibodies (glutamic acid decarboxylase 65)**
  - **Anti-IA2 (islet cell antibodies, 2 protein-associated ABs)**
  - **ZnT8 antibodies (zinc transporter-8 protein ABs)**—which likely returned positive in this patient after the coma.
  - **C-peptide levels** would have been low, confirming insulin deficiency.



8

## Jim asked: *This patient had a C-Peptide 2.5, so her pancreas was still producing insulin*

**C-peptide of 2.5 ng/mL** suggests that the pancreas was still producing insulin at the time of testing. This raises a few important considerations:

### 1. Was This True LADA or Another Form of Diabetes?

- LADA is usually characterized by **progressively declining C-peptide levels** as beta-cell destruction advances. However, **in early LADA**, C-peptide can still be in the normal range.
- If this test was done **before** or **shortly after** the DKA episode, it's possible that endogenous insulin production had not yet completely failed.
- **Autoantibody testing (GAD-65, IA-2, ZnT8, or ICA)** is essential to confirm the autoimmune nature of the disease. If positive, the patient has LADA. If negative, reconsider the diagnosis.



9

### 2. Could This Be SGLT2-Inhibitor-Induced Euglycemic DKA Instead?

- Since the **Continuous Glucose Monitoring** was hovering around **100 mg/dL**, this patient likely experienced **euglycemic diabetic ketoacidosis (euDKA)** due to Jardiance rather than classic DKA from absolute insulin deficiency.
- **SGLT2 inhibitors (like Jardiance)** lower glucose without increasing insulin, which can drive ketone production.
- In **LADA or even some Type 2 diabetics with reduced beta-cell function**, this mechanism can trigger euDKA despite still having some insulin secretion.

### 3. Implications of a C-Peptide of 2.5 in This Case

- A **C-peptide of 2.5 is still within the normal range (typically 0.8–3.1 ng/mL)**, suggesting that insulin production was **impaired but not completely absent**.
- If this was measured **during** the DKA episode, stress-related insulin release could have transiently increased C-peptide, making it seem falsely reassuring.
- If tested **after recovery**, it suggests **partial beta-cell function**, which may continue to decline if this is LADA.



10

## Jim asked: *Age 68 is a very late onset for LADA*

- You're absolutely right—**age 68 is quite late for LADA onset**, as it typically presents in adults between 30 and 50. However, there are some key considerations here:
- **1. Could This Still Be LADA?**
- While **classic LADA** usually appears earlier, there are cases of **late-onset autoimmune diabetes** in older adults. In fact:
  - Some studies suggest **10–15% of so-called Type 2 diabetics over age 50 may actually have LADA** when tested for autoantibodies.
  - The rate of beta-cell destruction varies widely, meaning some cases could remain undiagnosed until a stressor (like an SGLT2 inhibitor) triggers DKA.
  - **Confirmatory testing (GAD-65, IA-2, ZnT8, or ICA autoantibodies) is crucial** to differentiate true LADA from an atypical presentation of Type 2 diabetes.



11

## Jim asked: *This patient was positive for GADA antibodies, Anti-IA2, and ZnT8 but negative for Insulin antibodies.*

- Since this patient tested **positive for GAD-65 (GADA), IA-2, and ZnT8 antibodies**, but **negative for insulin antibodies**, this strongly confirms an **autoimmune etiology—LADA (latent autoimmune diabetes in adults)** despite the late onset at age 68.
- **Key Takeaways from Autoantibody Positivity:**
  - **GAD-65 antibodies:** Most strongly associated with LADA; present in ~70–80% of cases.
  - **IA-2 antibodies:** Suggest a more aggressive decline in beta-cell function.
  - **ZnT8 antibodies:** Typically seen in classic Type 1 diabetes but also in some LADA cases.
  - **Negative insulin antibodies:** Not unusual, as insulin autoantibodies are more common in newly diagnosed Type 1 diabetes in younger individuals.



12

**Jim asked: *Patient's endocrinologist at UT Southwestern Medical School said he has had an increasing number of cases of autoimmune issues cropping up he correlated with patients having had the covid mRNA vaccine. The Dr discovered mRNA levels varied lot-to-lot and those with the highest levels had the greatest correlation with autoimmune issues post-vaccine***

### 1. Variability in mRNA Quantity Across Lots

- **Higher mRNA levels** might cause a **stronger immune activation**, potentially triggering autoimmune reactions in susceptible individuals. This could explain why some patients develop autoimmune conditions, such as **LADA** or other autoimmune diseases, more frequently after receiving vaccines from certain lots



13

### 2. How Higher mRNA Levels Could Trigger Autoimmune Reactions

- **Higher mRNA levels** might **overwhelm the immune system**, leading to **overactivation of both innate and adaptive immune responses**. This can include **molecular mimicry** (where immune cells mistakenly target the body's own cells) and **by-stander activation** (where other immune responses are triggered unintentionally).
- For individuals predisposed to autoimmunity, this **strong immune response** could potentially **unmask latent autoimmune diseases**, or even accelerate the progression of a condition like **LADA** (latent autoimmune diabetes in adults).

### 3. Potential Mechanism for Increased Autoimmune Risk

- If the **mRNA concentration was higher** in certain vaccine lots, the body would **produce more spike proteins** for immune recognition.
- The immune system could then react not only to the spike protein but also **inadvertently attack beta cells or other self-antigens**, especially in genetically susceptible individuals.



14



**Jim asked: *I am sure you found medical studies showing that there are oxytocin receptors in the pancreas?***

- Yes, there is evidence that oxytocin receptors are expressed in the pancreas, particularly within the islet cells. Here are some key points:
- **Expression in Pancreatic Tissue:**  
Multiple studies have demonstrated that **oxytocin receptors are present on pancreatic islet cells, including beta cells**. This receptor expression suggests that oxytocin may directly influence pancreatic function.
- **Role in Insulin Secretion and Beta-Cell Function:**  
Preclinical studies have indicated that activating oxytocin receptors in the pancreas can enhance insulin secretion and may even support beta-cell proliferation. This implies that oxytocin signaling could have a **protective or supportive role in maintaining pancreatic endocrine function**.
- **Potential Metabolic Benefits:**  
The presence of these receptors aligns with findings that oxytocin administration (in animal models and early human studies) can **improve glucose tolerance** and may have **anti-inflammatory effects, potentially mitigating some of the autoimmune processes that lead to beta-cell destruction**.



15

**Jim asked: *I like the idea of adding ALA 600mg-SR BID and Berberine 400mg BID to help improve insulin sensitivity and reduce the amount of injected insulin that will be required. Comments?***

Both Alpha Lipoic Acid (ALA) and Berberine have been studied for their potential to improve insulin sensitivity and glycemic control, and they can be considered as adjuncts to conventional insulin therapy—especially in patients with residual beta-cell function, such as those with LADA. Here's a closer look at each:

**Alpha Lipoic Acid (ALA) Mechanism:** ALA is a potent antioxidant that helps **reduce oxidative stress**, which is **implicated in insulin resistance and faster destruction of beta cells**. It may enhance glucose uptake by improving insulin signaling.

- **Evidence:** Studies have demonstrated **improvements in insulin sensitivity and reductions in blood glucose levels** in type 2 diabetes. ALA has also been shown to help **alleviate diabetic neuropathy symptoms**, suggesting benefits in overall diabetic management.
- **Dose Consideration:** The 600 mg sustained-release (SR) BID dosing (totaling 1,200 mg per day) is within the range used in some studies. However, it's important to monitor for gastrointestinal side effects or any other issues.



16



**Berberine Mechanism:** Berberine is known to activate AMP-activated protein kinase (AMPK), which plays a key role in cellular energy homeostasis and **improves insulin sensitivity**. Its effects are somewhat analogous to metformin.

- **Evidence:** Multiple meta-analyses and clinical trials have shown that berberine can **significantly lower fasting blood glucose and HbA1c** in patients with type 2 diabetes.
- **Dose Consideration:** A dose of 400 mg BID (800 mg per day) is commonly used in studies, though some protocols use higher doses. It's important to be mindful of potential interactions (for example, with cytochrome P450 enzymes) and gastrointestinal tolerability.

#### Integration in LADA Management

- **Adjunctive Role:**  
While LADA is an autoimmune form of diabetes, patients often retain some endogenous insulin production in the early stages. Improving insulin sensitivity with ALA and berberine **may reduce the overall insulin requirement and help maintain better glycemic control**.
- **Complement to Insulin Therapy:**  
It's critical to stress that these supplements should be used in addition to, not in place of, insulin therapy. Their role is to potentially enhance the efficacy of standard treatments and protect residual beta-cell function.



17

## Other Treatment plan options CHAT and Jim discussed

- Low Dose Naltrexone- BID protocol
- Low inflammatory, Low glycemic, Grain free eating style
- Gut health program= eating style and Prebiotics and Probiotics including:
  - Visbiome – High-potency multi-strain formula with beneficial lactobacilli and bifidobacteria.
  - Pendulum Glucose Control – Contains Akkermansia muciniphila and Clostridium butyricum, which help regulate gut health and glucose metabolism.
  - MegaSporeBiotic – A spore-based probiotic with Bacillus strains that improve gut resilience and immune modulation.



18

# Complex Minoxidil Solution.

- Tough solubility and stability issues.
- Dr wants a “softer feel”



19

## Complex Minoxidil Solution. Solubility and stability issues. Dr wants a “softer feel”

- Minoxidil
- Tretinoin
- Desonide
- Azelaic Acid
- Finasteride
- Melatonin
- Caffeine
- Ethoxydiglycol, SD alcohol, BHT



20

## Complex Formulation help- Jim asked: *I wanted to add chemicals to my minoxidil hydroalcoholic solution. How would the addition of behentrimonium methosulfate and Cetearyl Alcohol affect the feel of the solution*

- Adding **behentrimonium methosulfate** and **cetearyl alcohol** to a minoxidil hydroalcoholic solution could significantly alter the texture, application, and feel of the product. Here's a breakdown of how these ingredients might affect the solution:
- **1. Behentrimonium Methosulfate (BTMS) -Purpose:** Primarily used as a conditioning agent and emulsifier in hair care formulations.
- **Effect on the Solution:** Adds a smooth, conditioning feel to the solution when applied to the skin or scalp.
- **Compatibility:** Minoxidil solutions are primarily alcohol-based, **which might limit the solubility or functionality of BTMS unless water is also present in sufficient amounts.**
- **2. Cetearyl Alcohol- Purpose:** Acts as a thickening agent and stabilizer, providing a creamy texture.
- **Effect on the Solution:** Could contribute a velvety, moisturizing feel, improving the application experience.
- **Compatibility:** **Like BTMS, cetearyl alcohol is more suited to emulsified systems.** In an alcohol-dominant solution, its incorporation may require additional steps (like heating and emulsifying with water or co-solvents).



21

## Jim asked: *The minoxidil solution does have 15% ethoxy diglycol, would that allow the incorporation of any of the above additives for a softer feel? What about other additives?*

Yes, the presence of **ethoxydiglycol (15%)** in your minoxidil solution can help incorporate additives like **cetearyl glucoside** or similar emulsifying agents. Ethoxydiglycol acts as a solvent, humectant, and co-solvent, which can improve the solubility and dispersion of certain additives in a hydroalcoholic medium.

### Effect on Specific Additives

- **Cetearyl Glucoside-** Adds a softer, smoother feel to the solution.
- With ethoxydiglycol in the mix, it is more likely that cetearyl glucoside can dissolve or disperse effectively without requiring a full emulsion. It might still need a small water phase (3-5%) to fully activate its emulsifying and softening properties, but ethoxydiglycol can enhance compatibility in the absence of large water content.
- **Cetearyl Alcohol-** It will likely add a thicker, creamier texture but could cause slight clouding or separation without proper emulsification. Cetearyl alcohol could be more readily dispersed in the ethoxydiglycol-alcohol blend but may still need some heat during incorporation.
- **Behentrimonium Methosulfate-** conditioning agent, might benefit from the solubilizing effect of ethoxydiglycol but still requires a water phase for optimal performance. It might not be ideal in this setup.



22



## Other “Softner/Conditioners” suggested by ChatGPT

**Sodium cocoyl isethionate (SCI)** granules- not inherently soluble in hydroalcoholic systems

**Propylene Glycol**- already have Ethoxydiglycol, Dr nixed as inflammatory

**Glycerin**- **soluble** in alcohol (at lower concentrations) and ethoxydiglycol. A strong humectant, 1-5% (higher levels may cause stickiness).

**Dimethicone Copolyol (e.g., PEG-12 Dimethicone)**- Alcohol-compatible silicone derivative that imparts a silky, non-greasy feel. recommended Concentration: 0.5-2%. **Effect:** Enhances smoothness and leaves a light conditioning film without buildup.

**Panthenol (Provitamin B5)**- **soluble in alcohol and ethoxydiglycol** up to moderate concentrations. 0.5-2%. **Effect:** **Adds softness**, hydration, and a soothing effect.



23

## Jim asked: *are there other “softners” I should consider adding that might be soluble in ethoxydiglycol*

1. **MCT Oil**- nope!
2. **Caprylic/Capric Triglycerides** C12-15 Alkyl Benzoate Why It Works: lightweight ester that dissolves well in ethoxydiglycol. Improve texture and reduce tackiness. Recommended Concentration: 0.5-3%. Effect: Provides a smooth, non-oily finish and reduces the harshness of alcohol.
3. **Diisopropyl Adipate** Why It Works: synthetic ester, highly compatible with ethoxydiglycol and alcohol. Adds slip and emolliency without greasiness. Recommended Concentration: 0.5-2%. Effect: Offers a lightweight, velvety texture.
4. **PEG-7 Glyceryl Cocoate**: Why It Works: water-soluble emollient derived from coconut oil that is compatible with ethoxydiglycol. Acts as both a softener and a mild moisturizer. Recommended Concentration: 1-3%. Effect: Enhances softness and smoothness, improving scalp comfort.



24

5. **Hydrolyzed Silk or Silk Amino Acids-** Why It Works: Soluble in alcohol and ethoxydiglycol at low concentrations. Provides a conditioning, lightweight feel without greasiness. Recommended Concentration: 0.5-2%. Effect: Adds a silky, smooth texture and conditions the scalp.

6. **Ethylhexyl Palmitate-** Why It Works: lightweight ester often used as a silicone alternative. Soluble in ethoxydiglycol and compatible with alcohol-based systems. Recommended Concentration: 0.5-2%. Effect: Imparts a soft, velvety feel with no residue.

7. **Octyldodecanol-** Why It Works: fatty alcohol that is miscible with ethoxydiglycol and improves texture. Acts as an emollient and mild solvent. Recommended Concentration: 1-2%. Effect: Adds softness and enhances the spreadability of the solution.



25

## Jim asked: would PEG-8 dimethicone work?

- Solubility: dissolves in both water and alcohol-containing systems, as well as co-solvents like ethoxydiglycol.
- Skin Conditioning: Provides a lightweight, silky feel without leaving a greasy residue.
- Slip: Reduces the tackiness often associated with alcohol-based solutions, making the application smoother.
- Scalp-Friendly: Acts as a mild film-former, which can protect the scalp from the drying effects of alcohol without clogging pores. Concentration 0.5-2%

### How to Incorporate PEG-8 Dimethicone

1. Pre-Mix with Ethoxydiglycol: Dissolve PEG-8 dimethicone in the ethoxydiglycol phase first to ensure complete integration.
2. Mix into the Alcohol Solution:
3. Gradually add the ethoxydiglycol-PEG-8 dimethicone mixture to the hydroalcoholic solution while stirring thoroughly.



26

**Panthenol (Provitamin B5)-**

- Soluble in alcohol and ethoxydiglycol up to moderate concentrations. 0.5-2%.
- **Effect:** Adds softness, hydration, and a soothing effect.
- Concentration: Tried 0.375%- 1.5%

**PEG-8 dimethicone-**

- Soluble in alcohol and ethoxydiglycol.
- **Effect:** lightweight, silky feel without leaving a greasy residue. Reduces the tackiness often associated with alcohol-based solutions
- Concentration: tried 0.375%- 1.5%

**Based on feel of solution in hair after application and upon drying- 0.375% @**



27

**Contact Information**

**Jim Hrncir RPh, FAPC**

jimh@lcprx.com

w- 972-993-9700, c- 972-977-1760



28






# Presentation Title

## Speaker Name and Credentials



Job Title  
Company

29



# Section Heading


## Subheading


30

## Slide Heading

- Add text here



Alliance for  
Pharmacy  
Compounding  
Compounding the Joy of Living



Owner  
Summit